Patents Examined by Christian C Boesen
-
Patent number: 11976382Abstract: The present disclosure relates to oligonucleotide biosensors that bind to a fluorophore through a reporter domain and to one or more target ligand(s) through one or more target domain(s), which is connected to the reporter domain through one or more linker domain(s). The binding of the target ligand to the target domain affects the fluorescence of the fluorophore when excited by the appropriate wavelength of energy, either by causing dimming or allosteric fluorescence. Methods of selecting biosensors and their use to detect target ligands are also described.Type: GrantFiled: October 20, 2020Date of Patent: May 7, 2024Assignee: Boise State UniversityInventors: Steven Burden, Eric Hayden, Nicholas Shults
-
Patent number: 11976381Abstract: The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system. The disclosed system of Comprehensive Integrated Antibody Optimization (CIAO!™) allows for simultaneous evolution of protein performance and expression optimization.Type: GrantFiled: January 27, 2021Date of Patent: May 7, 2024Assignee: BioAtla, Inc.Inventor: Jay Milton Short
-
Patent number: 11976384Abstract: Methods and systems for quantification of an abundance of one or more payloads (e.g. proteins) in a mixture (e.g. a complex mixture (e.g. in vivo)) using barcodes (e.g. peptide barcodes), binders (e.g. polypeptide binders), and binding agents (e.g. phage) are provided herein.Type: GrantFiled: November 3, 2021Date of Patent: May 7, 2024Assignee: Manifold Biotechnologies, Inc.Inventors: Pierce Ogden, Gleb Kuznetsov, Shane Lofgren, Kathleen Nudel, Hoong Chuin Lim, Karen Duffy, Jeffrey Chang
-
Patent number: 11976383Abstract: This disclosure provides compositions and methods for expressing and displaying isolated integral membrane proteins (IMPs) or fragments thereof in a native conformation on poxvirus extracellular virions and methods for screening, selecting, and identifying antibodies or antibody-like molecules that bind to a target IMP of interest.Type: GrantFiled: May 5, 2021Date of Patent: May 7, 2024Assignee: VACCINEX, INC.Inventors: Ernest S. Smith, Maria G. M. Scrivens, Loretta Mueller, Shuying Shi, Leslie A. Balch
-
Patent number: 11970787Abstract: The present disclosure provides methods, compositions, kits, and systems useful in the determination and evaluation of the immune repertoire. In one aspect, target-specific primer panels provide for the effective amplification of sequences of T cell receptor and/or B cell receptor chains with improved sequencing accuracy and resolution over the repertoire. Variable regions associated with the immune cell receptor are resolved to effectively portray clonal diversity of a biological sample and/or differences associated with the immune cell repertoire of a biological sample.Type: GrantFiled: February 4, 2021Date of Patent: April 30, 2024Assignee: Life Technologies CorporationInventors: Timothy Looney, Geoffrey Lowman, Lifeng Lin
-
Patent number: 11946162Abstract: The invention relates to methods and products for generating diverse libraries of genetic material. The products include libraries and constructed nucleic acids as well as kits and databases and systems thereof.Type: GrantFiled: March 17, 2021Date of Patent: April 2, 2024Assignee: Massachusetts Institute of TechnologyInventors: Dehua Zhao, Christopher A. Voigt, Michael Joseph Smanski
-
Patent number: 11946163Abstract: The invention describes a novel system for identifying optimized gRNAs for use in CRISPR/Cas9 genome editing platforms. The invention allows for the determination of specific gene alterations rendered by a particular gRNA, thereby permitting the generation of optimized gRNA libraries.Type: GrantFiled: June 24, 2021Date of Patent: April 2, 2024Assignee: KSQ Therapeutics, Inc.Inventors: Gregory V. Kryukov, Michael R. Schlabach, Jason J. Merkin
-
Patent number: 11932697Abstract: The present invention relates to a polypeptide comprising an antigen binding domain and a carrying moiety having an inhibiting domain that inhibits the antigen binding activity of the antigen binding domain, and having a longer half-life than that of the antigen binding domain existing alone, methods for producing and screening for the polypeptide, a pharmaceutical composition comprising the polypeptide, methods for producing and screening for a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH, and a fusion polypeptide library including a single-domain antibody whose antigen binding activity is inhibited by associating with particular VL, VH or VHH.Type: GrantFiled: September 17, 2021Date of Patent: March 19, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Hiroyuki Ishikawa, Naoka Hironiwa
-
Patent number: 11926926Abstract: Provided are compositions and methods for preparing and identifying antibodies having CDR3s that vary in sequence and in length from very short to very long which in certain embodiments may bind to a carbohydrate moiety or the active site of an enzyme. Libraries coding for antibodies with the CDR3s are also provided. The libraries can be provided by modifying a pre-existing nucleic acid library.Type: GrantFiled: June 9, 2020Date of Patent: March 12, 2024Assignee: Takeda Pharmaceutical Company LimitedInventor: Robert Charles Ladner
-
Patent number: 11920258Abstract: Antibody libraries comprising a plurality of heavy chain variable domains and/or a plurality of light chain variable domains, which comprise complementary determining regions (CDRs) found in naturally-occurring human antibodies, and methods of making such antibody libraries. The antibody libraries are free of members that comprise one or more liabilities affecting one or more features of such members. Further, the antibody libraries comprise members having heavy chain and/or light chain CDRs not found in the same naturally-occurring human antibody.Type: GrantFiled: January 29, 2021Date of Patent: March 5, 2024Assignee: RULES-BASED MEDICINE INC.Inventors: Andrew Raymon Morton Bradbury, Michael Frank Erasmus, Andre Teixeira
-
Patent number: 11913137Abstract: This application provides an improved screening method for the selection of target-binding proteins having desirable biophysical properties. The method combines mRNA display and yeast surface display in a way that takes advantage of the desirable attributes of both processes.Type: GrantFiled: June 8, 2021Date of Patent: February 27, 2024Assignee: Bristol-Myers Squibb CompanyInventor: Dasa Lipovsek
-
Patent number: 11912987Abstract: This invention describes a novel CRISPR/Cas9 target identification platform permitting the discovery of novel genes and pathways involved in the ability of T cells and NK cells to react against and generate an anti-tumor response.Type: GrantFiled: June 24, 2021Date of Patent: February 27, 2024Assignee: KSQ Therapeutics, Inc.Inventor: Micah Benson
-
Patent number: 11912778Abstract: Provided herein are polypeptides that bind to a transferrin receptor, methods of generating such polypeptides, and methods of using the polypeptides to target a composition to a transferrin receptor-expressing cell.Type: GrantFiled: August 15, 2022Date of Patent: February 27, 2024Assignee: Denali Therapeutics Inc.Inventors: Xiaocheng Chen, Mark S. Dennis, Mihalis Kariolis, Adam P. Silverman, Ankita Srivastava, Ryan J. Watts, Robert C. Wells, Joy Yu Zuchero
-
Patent number: 11912989Abstract: An objective of the present invention is to provide target tissue-specific antigen-binding molecules, antigen-binding molecules whose antigen-binding activity varies depending on the concentration of an unnatural compound, libraries comprising a plurality of the antigen-binding molecules which are different from one another, pharmaceutical compositions comprising the antigen-binding molecules, methods of screening for the antigen-binding molecules, and methods for producing the antigen-binding molecules. The present inventors created antigen-binding domains whose antigen-binding activity varies depending on the concentration of a small molecule compound or antigen-binding molecules containing an antigen-binding domain, and libraries comprising a plurality of the antigen-binding domains which are different from one another or antigen-binding domains, and demonstrated that the above-noted objective could be achieved by using the libraries.Type: GrantFiled: February 23, 2021Date of Patent: February 27, 2024Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Tomoyuki Igawa, Shigero Tamba, Shun Shimizu, Kanako Tatsumi, Shojiro Kadono, Hiroki Kawauchi, Kazuhiro Ohara, Masayuki Matsushita, Takashi Emura, Masaki Kamimura
-
Patent number: 11913138Abstract: Methods for screening of affinity reagents for many target proteins of interest simultaneously. Arrayed targets (e.g., peptide, protein, RNA, cell, etc.) are used in affinity selection experiments to reduce the amount of target needed and to improve the throughput of discovering recombinant affinity reagents to a large collection of targets.Type: GrantFiled: August 18, 2021Date of Patent: February 27, 2024Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Joshua Labaer, Kevin Gorman, Brian Kay, Jie Wang, Ji Qiu
-
Patent number: 11912756Abstract: Compositions, methods and uses of high-diversity nucleic acid library that encodes a plurality of antibodies or antibody fragments are presented. The high-diversity nucleic acid library comprises or is derived from (1) a VH-CDR1/2 sub-library, (2) a plurality of VH-CDR3 sub-libraries, and (3) a VL sub-library, each of which comprises a plurality of members. Preferably, each member of the sub-libraries comprises at least one random cassette that has a plurality of degenerate base positions. In an especially preferred embodiment, at least portions of at least two members of the VH-CDR1/2 sub-library, the plurality of VH-CDR3 sub-libraries, and the VL sub-library are recombined to form an expression library member in an expression library, where each member of the expression library encodes a distinct antibody or antibody fragment.Type: GrantFiled: April 21, 2021Date of Patent: February 27, 2024Assignee: NantBio, Inc.Inventor: Clifford Anders Olson
-
Patent number: 11912765Abstract: The present invention relates to certain new methods to select epitopes for antibodies. The present invention also provides a method of generating an antibody (e.g. a functional antibody) to a protein, said method comprising (i) identifying an antigenic epitope in said protein by exposing the protein to limited or restricted proteolysis by contacting the protein with at least one protease to form at least one digested, deconstructed or truncated version of the protein and at least one surface-exposed peptide that is cleaved off from the protein by the action of said protease and generating an antigenic epitope based on said surface-exposed peptide; and (ii) raising an antibody against the antigenic epitope. The present invention also provides antigenic epitopes and antibodies against such epitopes.Type: GrantFiled: September 29, 2021Date of Patent: February 27, 2024Assignee: OBLIQUE THERAPEUTICS ABInventors: Owe Orwar, Carolina Trkulja
-
Patent number: 11905623Abstract: Some aspects of the present disclosure provide methods for evolving recombinases to recognize target sequences that differ from the canonical recognition sequences. Some aspects of this disclosure provide evolved recombinases, e.g., recombinases that bind and recombine naturally-occurring target sequences, such as, e.g., target sequences within the human Rosa26 locus. Methods for using such recombinases for genetically engineering nucleic acid molecules in vitro and in vivo are also provided. Some aspects of this disclosure also provide libraries and screening methods for assessing the target site preferences of recombinases, as well as methods for selecting recombinases that bind and recombine a non-canonical target sequence with high specificity.Type: GrantFiled: August 10, 2021Date of Patent: February 20, 2024Assignee: President and Fellows of Harvard CollegeInventors: David R. Liu, David B. Thompson, Jeffrey L. Bessen
-
Patent number: 11866484Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.Type: GrantFiled: March 3, 2021Date of Patent: January 9, 2024Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
-
Patent number: 11834757Abstract: The present specification provides libraries of HLA homozygous induced pluripotent cell lines.Type: GrantFiled: December 5, 2018Date of Patent: December 5, 2023Assignee: New York Blood Center, Inc.Inventors: Pablo Rubinstein, Christopher D. Hillyer